Skip To Main Content
Ying-Jun Chang on Muck Rack

Ying-Jun Chang

As seen in: Color Research & Application, Nature, Wiley Online Library, Frontiers, The BMJ, The Lancet, Journal of Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Jun

Contact Ying-Jun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial

|
By Peng Zhao, Zhuo-Yu An, Hai-Xia Fu, Yang Wang, Hui-Xin Liu, Dai-Hong Liu, Yi Liu, Zhao Wang, Yu-jun Dong, Hong-Mei Jing, Li-Hong Li, Qiu-Sha Huang, Jin Wu Verified, Li-Ping Yang, Yue Jin, Chen-Cong Wang, Qi Chen, Xiao-Lu Zhu, Yun He, Yuan-Yuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Jun Huang, Xiao-Hui Zhang, Guo-Shuang Feng, He-Bing Zhou, Zhen-Ling Li, Li-Ping Dou, Zhi-Xue Li
| Nature Verified
Abstract This multicenter, randomized, controlled study was conducted to explore the safety and efficacy of low-dose baricitinib plus danazol for ITP patients who had failed corticosteroids and at least one recommended subsequent treatment. Participants were randomly assigned to receive baricitinib plus danazol (n = 108) or danazol alone (n = 108) by a central, interactive web-based system. Patients and caregivers were not blinded to group assignment.
Open in Who Shared Issue with article?

Second alternative-donor haploidentical stem cell transplantation enhances survival in patients with myeloid malignancies complicated by posttransplant human leukocyte antigen loss relapse

|
By Xiao-Tong Chen, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Xiao-Dong Mo, Xiao-Su Zhao, Xiao-Jun Huang, Ying-Jun Chang, Ze-Chang Shi, Ming-Rui Huo
| Nature Verified
Presently, haploidentical stem cell transplantation (haplo-SCT) has emerged as an alternative therapy for patients with myeloid malignancies [1]. Despite remarkable advances in haplo-SCT, relapse remains the primary cause of treatment failure [2]. Notably, second SCT (SCT2) is the main therapy for patients who relapse after the first haplo-SCT, with 2-year overall survival (OS) of 28.7% [3]. However, the optimal donor for SCT2 is still debated [4,5,6].
Open in Who Shared Issue with article?

Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience | Bone Marrow Transplantation

|
By Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Yi-Fei Cheng, Xiao-Dong Mo, Yu-Qian Sun, Ya-Zhen Qin, Ying-Jun Chang
| Nature Verified
To the Editor: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is considered a curative treatment modality for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and has improved the long-term survival since the integration of tyrosine kinase inhibitors (TKIs) into chemotherapy and post-transplant maintenance [1]. However, relapse still occurs in up to 30% of patients; in that case, survival outcomes are still unsatisfactory [2].
Open in Who Shared Issue with article?
See all 15 articles